Opportunities and Challenges of Arginase Inhibitors in Cancer: A Medicinal Chemistry Perspective
Journal of Medicinal Chemistry · 28.11.2024 · 67 (22) · 19988-20021
DOI: 10.1021/acs.jmedchem.4c01429 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 19.11.2024. Verfasst von Mariacristina Failla und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy. Hauptthemen laut MEDLINE: Arginase, Neoplasms, Enzyme Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 157 Literaturangaben. Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS, Universit? degli Studi di Torino, Ministero dell'Universit? e della Ricerca.
Abstract (Originalsprache)
The overexpression of two arginase (ARG) isoforms, ARG1 and ARG2, contributes to the onset of numerous disorders, including cardiovascular and immune-mediated diseases, as well as tumors. To elucidate the specific roles of ARG1 and ARG2 without interfering with their physiological functions, it is crucial to develop effective ARG inhibitors that target only one isoform, while maintaining low toxicity and an adequate pharmacokinetic profile. In this context, we present a comprehensive overview of the different generations of ARG inhibitors. Given the general lack of selectivity in most existing inhibitors, we analyzed the structural features and plasticity of the ARG1 and ARG2 binding sites to explore the potential for designing inhibitors with novel binding patterns. We also review ongoing preclinical and clinical studies on selected inhibitors, highlighting both progress and challenges in developing potent, selective ARG inhibitors. Furthermore, we discuss medicinal chemistry strategies that may accelerate the discovery of selective ARG inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy.
- Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy.
ORCID-Profile: Marta Serafini, Konstantin Chegaev, Loretta Lazzarato, Francesca Spyrakis, Federica Sodano
Förderung
- Fondazione AIRC per la ricerca sul cancro ETS
- Universit? degli Studi di Torino
- Ministero dell'Universit? e della Ricerca
Zitieren
APA
Failla, M., Molaro, M. C., Schiano, M. E., Serafini, M., Tiburtini, G. A., Gianquinto, E., Scoccia, R., Battisegola, C., Rimoli, M. G., Chegaev, K., Ercolano, G., Lazzarato, L., Spyrakis, F., & Sodano, F. (2024). Opportunities and Challenges of Arginase Inhibitors in Cancer: A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry, 67(22), 19988-20021. https://doi.org/10.1021/acs.jmedchem.4c01429
Vancouver
Failla M, Molaro MC, Schiano ME, Serafini M, Tiburtini GA, Gianquinto E, et al. Opportunities and Challenges of Arginase Inhibitors in Cancer: A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry. 2024;67(22):19988-20021. doi:10.1021/acs.jmedchem.4c01429
BibTeX
@article{Failla2024,
author = {Failla, Mariacristina and Molaro, Maria Cristina and Schiano, Marica Erminia and Serafini, Marta and Tiburtini, Gioele Antonio and Gianquinto, Eleonora and Scoccia, Riccardo and Battisegola, Chiara and Rimoli, Maria Grazia and Chegaev, Konstantin and Ercolano, Giuseppe and Lazzarato, Loretta and Spyrakis, Francesca and Sodano, Federica},
title = {Opportunities and Challenges of Arginase Inhibitors in Cancer: A Medicinal Chemistry Perspective},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {22},
pages = {19988--20021},
doi = {10.1021/acs.jmedchem.4c01429}
}
EUVIMED